Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10987649 | 0.81 | TSHR (0.50) | SMN1; SMN2RAB9ATSHRMITFALDH1A1 | |
| SCHEMBL4967856 | 0.75 | — | — | |
| SCHEMBL6159480 | 0.69 | SMN1; SMN2 (0.34) | SMN1; SMN2RAB9ATSHRMITFALDH1A1 | |
| SCHEMBL15703047 | 0.68 | MEN1 (0.39) | TSHRALDH1A1LMNA | |
| SCHEMBL29373909 | 0.67 | CYP11B1 (0.37) | RAB9AALDH1A1 | |
| SCHEMBL31725530 | 0.67 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9AMITFALDH1A1LMNA | |
| SCHEMBL9674402 | 0.67 | HTT (0.55) | SMN1; SMN2RAB9AMITFALDH1A1LMNA | |
| SCHEMBL15705467 | 0.66 | APOBEC3G (0.37) | TSHRALDH1A1LMNA | |
| SCHEMBL31716780 | 0.65 | HTR2A (0.36) | SMN1; SMN2RAB9ATSHRMITFALDH1A1 | |
| SCHEMBL22245252 | 0.65 | RAB9A (0.33) | SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320527-B1 | METHOD FOR PRODUCING 1 SUBSTITUTED 5-CHLORO-4 METHYL PYRAZOLES | BASF SE (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-7002023-B2 | Method for producing 1 substituted 5-chloro-4 methly pyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-21 | — | — | US | disclosed |
| US-20040102505-A1 | Method for producing 1 substituted 5-chloro-4 methly pyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102505-A1 | Method for producing 1 substituted 5-chloro-4 methly pyrazoles | CYP4F2, CYP2F1, CYP4F3 | SMN1; SMN2 4772/4885RAB9A 2335/4885TSHR 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.